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 INTRODUCTION 
                               The last 100 years have seen the incidence of lung 
cancer transformed from it being an almost unknown disease to it far 
outstripping all other forms of cancer as a cause of death in many countries. 
In men it is responsible for about 40% of cancer deaths and in women it 
now rivals breast cancer as the major cause of cancer mortality. 
                                  Many developing countries have a relatively low 
incidence of lung cancer but are beginning to see the rises already 
experienced elsewhere as the inhabitants take to smoking in increasing 
numbers. 
                                 Lung carcinoma is largely a disease of the elderly and 
this tumor is very rare in children but occasional cases are encountered. It 
carries a very poor prognosis as spread of the tumor often results in it being 
inoperable at presentation while many patients with lung carcinoma have 
coexistent chronic obstructive lung disease that renders them unfit for 
surgery. Overall 5 year survival rates vary from 6-20%. 
                                  Lung carcinomas fulfill many of the following criteria 
for successful screening programme : the condition is common ,the 
population at risk is well known and premalignant changes can be detected 
cheaply(eg,sputum cytology).Unfortunately the premalignant changes 
cannot be easily eradicated as there is no bronchopulmonary equivalent of a 
uterine cone biopsy. Nor does screening for early invasive growths by a 
combination of sputum cytology and radiography appear to reduce 
mortality. 
                        Transthoracic biopsy is a safe and effective procedure in the 
evaluation of benign lesions, undetermined pulmonary lesions and an 
important tool in those patients with a peripheral mass inaccessible by 
bronchoscopy. 
                    The methods that are commonly used are for obtaining 
materials for pathological diagnosis are: 
                                 1) Core needle biopsy by radiological intervention 
                                 2) Transbronchial biopsy 
                                 3) Transthoracic needle aspiration    
             Our study is based on histomorphological profile of lung tumors on 
CT/USG guided core needle biopsies  
 
 
 
 
 
 
 
                                                     AIMS AND OBJECTIVES 
1) To study the histomorphological variants of lung tumors on CT/USG 
guided core needle biopsy specimens. 
2) To study the age, sex and site of prevalence of various histopathological 
variants of lung tumors. 
3) Employing PAS and immune markers in selective cases. 
4) To define morphological criteria in various subtypes of lung cancers. 
 
 
 
 
 
 
 
                                           
  REVIEW OF LITERATURE  
                                             Transthoracic biopsy is an important diagnostic 
tool in those patients with a peripheral mass inaccessible by bronchoscopy 
thus hindering the diagnosis by transbronchial biopsy.Pulmonary needle 
biopsy was used by Leyden in 1883 to detect microorganisms (Leyden H et 
al )20.Three years later Menetrier succeeded in diagnosing pulmonary 
neoplasms by transthoracic aspiration.Needle aspiration and biopsy has been 
in widespread use in recent years with an acceptable safety. 
                                               CT/USG  guided percutaneous transthoracic 
biopsy is a safe and effective procedure in the evaluation of undetermined  
pulmonary lesions and also permits successful drainage of pulmonary 
abscesses(Mathis G et al) 23.According to Kardos et al and Davies et al ,this  
technique is particularly useful for benign lesions or tumors with 
pleomorphic morphological charecteristics and has better diagnostic value 
relative to bronchoscopic sampling in those cases where the size and 
location of the nodule make it inaccessible with the bronchoscopy.4,17 
                                           Thoracotomy in almost every case provides 
sufficient material for a definite diagnosis and has the added advantage that 
in a small percentage of patients with malignant lesions an attempt at 
curative curative resection  can also be made.But Steal et al30 stated that 
most lesions ,atleast in the older  population ,can be expected to be 
malignant and that ,of these, the majority on clinical grounds be 
nonresectable at the time of presentation.In addition ,a number of patients 
will have benign lesions which do not require surgical treatment and also 
some will have small cell carcinoma for which chemotherapy is preferred.30 
                                                       In light of these considerations and of the 
considerable morbidity associated with thoracotomy it is desirable in most 
patients to establish a diagnosis by a closed procedure.Percutaneous needle 
biopsy provides a mean of accomplishing this. 
                                                     The modalities commonly employed for 
the image guided percutaneous needle biopsy include fluoroscopy, 
conventional CT/USG,helical CT(which is more commonly used)(Wiscott 
et al).35CT fluoroscopy ,which was established most recently, has simplified 
the process and has decreased the time required for CT scan guided needle 
biopsies 
.                                                     According to Haramati et al,the various 
kind of needles used are divided into the following two types: the modified 
trucut and modified Menghini type.11The Trucut type of needle consists of 
an outer cutting cannula and an inner trocar that contains the specimen 
notch. In general the following procedure is used with this type of needle. 
When the tip of the needle reaches the lesion ,the inner trocar is thrust 
forward ,followed by a forward thrusting of the outer cutting 
cannula.(Takuji Yamagami et al).33The specimen is then trapped in the 
notch of the trocar when the cutting cannula is advanced.   
                                                         The Menghini type, which is also known 
as full cut type needle, consists of an inner trocar that does not have a notch 
and an outer cutting cannula.When the tip of the biopsy needle reaches the 
lesion,the outer cutting cannula is advanced ,while the inner trocar is held 
stationary and the tissue core is captured inside the outer cannula.The 
Menghini type needle creates a vaccum in the end of the outer needle when 
the outer cutting cannula is thrust forward. 
                                                            Biopsy is taken with Trucut disposable 
needle following premedication with atropine and infiltration of the chest 
wall with lignocaine.A tissue core of 2 by 20 mm in size is obtained and 
should preferably be placed in saline solution or fixative under negative 
pressure so that collapsed alveolar spaces may become inflated. 
INDICATIONS: 
1) To differentiate malignant from benign lesions  
2) When the diagnosis of malignancy by FNAC is uncertain 
3) More detailed characterization of the lesion is required 
4) As a safe and reliable procedure in elderly with suspected 
chest malignancy 
5) As an important diagnostic tool in those patients with 
peripheral pulmonary mass inaccessible by bronchoscope. 
 
INTERPRETATION OF BIOPSY SPECIMENS: 
                                               According to Quint et al26 the results are 
classified into following 4 groups: 
                            1) Positive or suspicious for malignancy 
                            2) Benign specific 
                           3) Benign non specific 
                           4) Non diagnostic 
 The diagnosis of benign lesion is to be made only if a) there was a complete 
or near complete core of tissue available and b) there was sufficient 
morphological detail to make a confident diagnosis of a benign process. In 
addition it was recognized that a very small specimen of inflammatory or 
necrotic tissue could not exclude a diagnosis of malignancy and such cases 
were included in the nondiagnostic category.6 
 Further nondiagnostic biopsy specimens were classified into 3 types: 
                           1) No material is obtained 
                          2) Normal lung tissue is biopsied 
                           3) Specimen too small and distorted to make a diagnosis. 
                                    There are reasons for which a diagnosis could not be 
reached on the biopsy material: a) locality of the lesion: According to Yang 
et al,37the sensitivity of diagnosis of malignancy was 96.8% and accuracy 
was 97.5% in case of sub pleural tumors and the sensitivity of diagnosis  of 
malignant tumors located within the lungs was 94.6% and accuracy was 
95.2%. 
                                                   The size of the lesion of the lesion does not 
influence much on the adequacy of the biopsy material. According to 
Laurent et al, 19the accuracy of CT/USG guided biopsy nodules smaller than 
20 mm, are comparable to those of larger lesions. 
COMPLICATIONS: 
1) Uncontrollable hemorrhage: There is a relatively high 
incidence of severe hemorrhage in diffuse pulmonary 
disease than in localized mass lesions as blood vessels 
penetrate through the lung in a normal fashion in diffuse 
pulmonary disease (Douglas et al)6 
2) Pneumothorax(Halil et al)12 
3) Emphysema(Lourenco et al)18 
4) Hemoptysis(Galfieri et al7 
5) Air embolism 
6) Tumor implantation along the needle tract 
 
CONTRAINDICATIONS: 
                                           1) Chronic respiratory insufficiency 
                                           2) Pulmonary arterial hypertension 
                                           3) Hemorrhagic diathesis 
                                            4) Highly vascular lesions 
                                            5) Echinococcal infections 
HISTOLOGICAL CLASSIFICATION OF LUNG CARCINOMAS: 
                                                    The WHO classification of lung cancers is 
based upon differentiation in the whole tumor, and has no provision for 
making a non specific diagnosis that could be further refined if further 
material becomes available. Lung cancers are frequently heterogeneous and 
biopsy specimens provide only a small amount of tissue from which to make 
a preoperative diagnosis. Acccording to Edwards et al,27only 10-15% of 
patients with lung cancer will have tumor resected and the preoperative 
tumor classification confirmed. Therefore most patients”treatment will be 
based upon the diagnosis from preoperative specimens alone. 
                              Though there is a spectrum of different histological types 
of lung cancers like squamous cell, small cell,adeno,adenosquamous ,large 
cell neuroendocrine carcinomas etc,it is imperiative to classify lung cancers 
as small cell carcinomas(SCLCS) and non small cell carcinomas(NSCLCS) 
as treatment protocol is different for SCLCS and NSCLCS.(Delik Erman et 
al).6 
 
SMALL CELL CARCINOMAS: 
                                               Small cell carcinoma occurs generally in major 
airways, grows rapidly, metastasis early and initially at least is sensitive to 
chemotherapy. According to Betticher et al1, small cell carcinoma cells have 
                             1) Small uniform round or spindle cells arranged in 
sheets/ribbons/rosettes 
                           2) Nucleus with fine stippled chromatin and inconspicuous 
nucleoli 
                           3) Thin nuclear membrane 
                           4) Ill defined cell borders 
                           5) High mitosis and necrosis may be present. 
 
                        Small cell carcinoma is liable to be mistaken for large cell 
carcinoma  
 
 
.The main differentiating points are: 
  small cell ca large cell ca 
cell shape Fusiform polygonal 
N/C ratio High low 
chromatin Fine coarse 
Nucleoli Indistinct prominent 
 
A study conducted by Delik Erman et al6 of 571 cases of lung carcinomas 
between 1994-99 revealed that small cell carcinoma constituted only 31 % 
of cases and most of the cases had extensive disease at presentation. 
                     Undifferentiated carcinoma of small cell type is composed of 
small tumor cells with 
1) hyper chromatic ,coarsely granular or vesicular 
nucleus, 
2) small but distinct nucleoli  
3) scant but identifiable cytoplasm 
4) Distinct cell border. 
Tumors of this cell type may be classified as squamous cell carcinoma of 
small cell type. 
 
 NON SMALL CEL CARCINOMAS: 
                                                       This entity composes about 70 % of lung 
cancers and includes all categories except small cell carcinomas. They are: 
                           1) Squamous cell carcinoma 
                           2) Adenocarcinoma 
                           3) Large cell carcinoma 
                           4)Adenosquamous carcinoma 
                             5) Bronchial gland carcinoma-adenoidcystic carcinoma 
and mucoepidermoid carcinoma 
                            6) Miscellaneous tumors 
SQUAMOUS CELL CARCINOMA: 
                                                            Squamous cell carcinoma most often 
involves the central portion of the lung, arising from the large bronchi. 
Approximately one third however are peripheral tumors. There is a strong 
relationship with cigarette smoking and other carcinogens. It usually has a 
long natural history and evolves from gradually accumulating epithelial 
changes throughout the bronchial tree over many years. 
                                                 As the tumor progresses, it forms an 
endobronchial mass causing bronchial obstruction.Squamous cell 
carcinomas occurring in the periphery of the the lung are usually cavitary 
due to extensive necrosis.   
                                                           According to Suprun et al, 32 a high 
accuracy of diagnosis can be achieved for squamous cell carcinoma by 
adhering to criteria like 
                   1) Keratin formation  
                   2) Intercellular bridges 
                   3) Coarse, diffuse chromatin 
                   4) Dense shrunken nucleus 
                   5) Less conspicuous nucleoli 
                  6) Geographic necrosis uncommon 
                             
In cases where these features were absent,squamous cell carcinoma has 
intraepithelial insitu like extensions along the bronchus and  neither small 
cell carcinoma nor adenocarcinoma replaces the bronchial epithelium to any 
considerable extent and most of the cases are either well or moderately 
differentiated. This feature is useful in histological typing of lung cancers in 
small biopsy specimens.31 
                              Variants of squamous cell carcinomas have been 
described that have prognostic significance. 
                      1) Papillary variant- this variant tends to be well differentiated 
and has an excellent prognosis. 
                      2) Small cell variant-this variant reveals areas that contain 
small tumor cells with little cytoplasm and without intercellular bridges 
gradually blending with more clear cut evidence of squamous 
differentiation. 
                    3) Basaloid variant-nodular or trabecular growth pattern with 
peripheral palisading of the basal layers of malignant squamous cells along 
the basement membrane reminiscent of basal cell carcinoma. 
                          Both small cell and basaloid variants carry a poor prognosis. 
Other rare variants are clear cell, giant cell and spindle cell variants have 
been observed. The grading of squamous cell carcinoma could not be done 
from small biopsy specimens.3 
                      
ADENOCARCINOMA: 
                                        Adenocarcinoma is an invasive tumor showing 
varying morphology with papillary,acinar and solid patterns. They are more 
common in women than men and tend to be more often peripheral in 
location than squamous cell carcinoma or small cell carcinoma. These 
tumors show an increase in its incidence that cannot be ascribed solely to 
changes in histological typing. There is also an increased proportion of 
adenocarcinoma in non smokers and in the young  
                                              The individual cells exhibit features like 
                                    1) Enlarged nuclei 
                                    2) Peripheral clumping of chromatin 
                                    3) Prominent nucleoli 
                  Histologically  adenocarcinoma is a heterogeneous group of 
tumors that shows variation in architecture, hence the mixed type is the most 
common pattern observed. The other common patterns are 
                               1) Acinar pattern 
                               2) Papillary pattern 
                               3) Micro papillary pattern 
                               4) Bronchi alveolar pattern 
                               5) Solid pattern. 
Multicentricity of the tumor may be seen in approximately 20% of cases 
with tumor nodules present in other areas of the lung tissue. 
                             The diagnosis of adenocarcinoma seems to be more of a 
challenge as mucin and gland formation are frequently not present in small 
biopsy .They require the demonstration of glandular elements by using 
special stains like PAS.Thomas et al, 34 advocated the use of non small cell 
category (NSCLC) in cases where definite features of differentiation were 
absent, but the lesion lacked the features of small cell carcinoma. 
                                 According to Delik Erman et al,6among NSCLC, 
squamous cell carcinoma constituted the predominant group with 
60%,adenocarcinoma with 30% and large cell carcinoma comprising about 
5% and others 5%.NSCLC occurred predominantly in 50-80 years. Only 3% 
of cases presented before 30 years.Yutaka Mizushima38 et al stated that 
under the age group of 30 years, a high incidence of female gender, low 
incidence of squamous cell carcinoma and adenocarcinoma constituted the 
predominant histological type with favorable prognosis. 
 
LARGE CELL CARCINOMA: 
                                                    This tumor is charecterised by sheets of 
large cuboidal cells without evidence of cytoplasmic differentiation on 
routine stains.This tumor shows the greatest degree of interobserver 
variability among the pathologists.29 
                                                           A diagnosis of large cell carcinoma 
cannot be diagnosed on small biopsy as they are considered poorly 
differentiated forms of either squamous,adeno or neuroendocrine carcinoma 
and all major histological types of lung carcinomas may contain foci of 
features of large cell carcinoma .So  the diagnosis of large cell carcinoma is 
based on the resected specimens.(Edwards et al).27 
ADENOIDCYSTIC CARCINOMA: 
                                                               Adenoidcystic carcinoma is a rare 
lung malignancy that occurs in a wide age range .Hilal Alunoz et al10 stated 
that it occurred predominantly in the trachea where it constituted the most 
common malignancy next to squamous cell carcinoma. Only 10 -15 % of 
cases occurred in the periphery. Most common histological pattern is 
cribriform with many microcystic spaces containing PAS positive 
eosinophilic secretions. 
MUCOEPIDERMOID CARCINOMA: 
                                                              Mucoepidermoid carcinoma is a very 
rare entity that predominantly occurs in younger age group with equal sex 
incidence. Xiuli et al 36stated that it commonly arises from the sub mucosal 
glands of bronchi and it is usually well differentiated usually composed of 
mucinous cells,squamoid and intermediate  cells. The occurrence of this 
particular tumor in young patients is due to recurrent translocations like t (1; 
11), t (11:19). 
CARCINOID: 
                      They are neuroendocrine tumors of low grade malignancy 
which comprises <1% of lung tumors. The mean age of presentation is 55 
years with equal sex incidence. About 8% of cases develop in the second 
decade where it is considered the most common pulmonary tumor of 
childhood.3They are not related to smoking or other pollutants. They do not 
appear to dedifferentiate into small cell or large cell neuroendocrine 
carcinoma. Several histological patterns are recognized, the most common 
being insular pattern. 
                                      Microscopically, the tumor cells are: 
1) uniform and generally polygonal  
2)  moderate amount of eosinophilic 
cytoplasm 
3)  round nuclei with fine granular chromatin  
4) And inconspicuous nucleoli. 
5) Mitosis is occasional and if present, <2/10 
hpf. 
6) If necrosis and or mitosis more than 2 /10 
hpf,the alternate diagnosis of small cell 
carcinoma or atypical carcinoid to be 
diagnosed. 
 
 
 
INFLAMMATORY MYOFIBROBLASTIC TUMOR: 
                                                                   Inflammatory myofibroblastic 
tumor is  a benign tumor of undetermined etiology that occurs in the age of 
less than 40 years with female predominance .Mahele et al21 stated that it 
commonly presented as an asymptomatic solitary nodule with systemic 
features like fever, increased ESR due to the cytokines secreted by the 
tumor.Histologically it is composed of three basic patterns1)organizing 
pneumonic pattern in which airways are filled with plump fibroblasts and 
histiocytes and parenchyma replaced with histiocytes ,fibroblasts and 
mononuclear cells.2)fibrohistiocytic pattern which is the most common 
pattern in which myofibroblasts are arranged in whorls(Hiroyuki Sakurai et 
al)13 3)lymphohistiocytic pattern ,the least common pattern in which 
polymorphs,,plasma cells, vacuoloted histiocytes and fibroblasts occupy the 
predominant cell types.  
ADENOSQUAMOUS CARCINOMA: 
                                                      Adenosquamous carcinoma is a distinct 
tumor entity that carries a poor prognosis compared to conventional 
squamous cell and adenocarcinoma.It is a relatively rare entity with a 
frequency of  1 -4 %.The diagnosis is based on the light microscopy which 
should reveal that both the adeno and squamous cell component  exhibiting 
malignant features and both components should constitute more than 
10%.according to Takamari et al.28The prognosis is not based on the relative 
proportions of adeno or squamous components but  due to the increased 
inherent potential of this tumor to metastasis to regional lymph nodes. The 
most common age group is 60 -70 years with increased male incidence and 
most of these tumors occur in the periphery of the lung. The histology of 
this tumor is uncertain .It may arise from adenocarcinoma with squamous 
metaplasia, collision tumor, high grade mucoepidermoid carcinoma and 
bipotential undifferentiated cell origin. 
BRONCHIOALVEOLAR CARCINOMA: 
                                               Bronchioalveolar carcinoma is a tumor that 
commonly occurs in females of middle to late age group .It is a variant of 
adenocarcinoma which lacks stromal, vascular and pleural 
invasion(Hiroyuki et al)13.It commonly occurs in the periphery of the lung. 
Therefore this category is reserved for adenocarcinomas that show a non 
invasive, non destructive pattern of mural growth throughout. 
Microscopically it is divided into two types 
                                            1) Mucinous type 
                                            2) Nonmucinous type 
Mucinous type: 
                             The tumor is formed by well differentiated mucin 
containing  columnar cells that line respiratory spaces without invading the 
stroma.The cells are relatively monomorphic,show little atypia,and produce 
large amounts of mucin leading on to bronchorroea. Continuity between the 
tumor cells lining alveoli and the epithelium of respiratory bronchioles or 
alveolar spaces can be demonstrated. A sharp demarcation is often between 
the neoplastic and the normal cells, an useful diagnostic feature. It carries a 
worst prognosis compared to non mucinous type. 
Nonmucinous type: 
                               They comprise 70% of cases of bronchioalveolar 
carcinoma. The tumor cells(clara cells or type 2 pneumocytes) are cuboidal 
rather than columnar and contain bright eosinophilic cytoplasm. The degree 
of nuclear atypia and nucleolar prominence is greater than mucinous variety. 
Hob nail cells may be present. Apical snouts may be present as indicator of 
clara cells. Cilia are characteristically absent and their presence should 
suggest the possibility of reactive condition. Incontrast to mucinous variant, 
various degrees of interstitial fibrosis and chronic inflammatory cells are 
present. 
It carries an excellent prognosis and local excision may be curative.  
CHARECTERISTICS OF LUNG CARCINOMA ACCORDING TO 
AGE GROUP AND SEX: 
                                               Age is considered as a risk factor for the 
development of lung cancer with a high percentage of cancers found older 
than 65 years. In this age group, there is a high percentage of non smokers 
and females. 
                                              Squamous cell carcinoma is the most 
predominant tumor in all age groups but the proportion of adenocarcinoma 
is higher in patients <60 years (de Parot et al)5that is adenocarcinoma is  
mainly observed in patients less than 60 years. Guntulu et al9 noted that 
adenoarcinoma and small cell carcinoma were predominant in the younger 
age group whereas squamous cell carcinoma occurred predominantly in the 
old age group. Michaela et al24 also pointed out that young patients were 
significantly found to have adenocarcinoma more when compared to old 
patients. 
                                                    Also the proportion of female cases was 
increased due to the changing pattern in the female smoking habit. A study 
was conducted by Yutaka Mizushima et al 38 to analyze various histological 
types and prognosis of lung carcinomas <30 years with those of older 
patients. Under the age group of 30 years ,a high incidence of female gender 
,a low incidence of squamous cell carcinoma, preponderance of 
adenocarcinoma with more favorable  prognosis were observed. 
Adenocarcinoma composed of 46% of all tumors, squamous cell carcinoma 
4%,small cell carcinoma4%,large cell carcinoma 15% and bronchial gland 
carcinoma like mucoepidermoid and adenoidcystic carcinoma accounted for 
19% . 
                                In the age group of 30 -49 years, adenocarcioma 
constituted the predominant category accounting for 61%,squamous cell 
carcinoma 13%,small cell carcinoma 9%,large cell carcinoma 13%,and 
adenosquamous carcinoma4%.Delik  Erman 6stated that under the age group 
of 45 years NSCLC occurs infrequently. 
                In the age group of 50-69 years, again adenocarcioma constituted 
the predominant histological type with 37%, small cell carcinoma 27%, 
squamous cell carcinoma24%, large cell and adenosquamous carcinoma 
constituted 5% each.Brambilla et al 2stated that adenocarcinoma constituted 
the predominant histology under the age group of 50 years 
                In the age group of >70 years squamous cell carcinoma 
constituted the predominant type with 43%,adenocarcinoma 30%,small cell 
carcinoma17%,large cell carcinoma constituted 5%,adenosquamous 4% and 
carcinoid 2%. 
ROLE OF IHC: 
                         The expression of cytokeratins (CK)  in human lung cancers 
is studied using monoclonal antibodies to cytokeratins 4,5,7,8,10,18 and 
19.( Jos LV Broers et al)16.When applied to adenocarcinoma,high level of 
cytokeratins 7,8 and  and 18 are detected with higher concentrations of 
cytokeratin 7.Thus monoclonal antibody specific for cytokeratin 7 can 
therefore be helpful to distinguish adenocarcinoma from other non small cell 
carcinoma.Masahika22 too stated that  positivity of staining of cytokeratin 7 
was found in 95.4% of adenocarcinomas. 
                            Squamous cell carcinoma expresses cytokeratin 4,5 and 14 
.Further Masahika et al22 stated that squamous cell carcinoma of lung are 
usually well to moderately differentiated  and IHC is usually not required to 
arrive at the diagnosis .Further he stated transbronchial and CT guided 
biopsy  are often performed to obtain a pathological diagnosis but the 
material obtained  may be  insufficient  for immunophenotyping  to be 
performed .   
                         These staining patterns are not absolutely specific as 
squamous cell carcinomas tend to express cytokeratins 8 and rarely 
cytokeratin 7.Some small cell carcinoma and carcinoid tend to express 
cytokeratin 18. (Johansson et al).15 
                          The neuroendocrine tumors express a panel of markers like 
NSE (neuron specific enolase),chromagranin ,synaptophysin etc but none of 
the antibodies are totally specific .Moreover Brambilla2 stated that in small 
biopsy specimens NSE appeared to the first screening marker for 
neuroendocrine tumors. 
                 Therefore because of considerable overlapping, 
immunophenotyping should not be used alone for histopathological 
classification of lung tumors but only to an adjuvant to light microscopy. 
 
 
 
 
 
 MATERIALS AND METHODOLOGY 
 The core material forming the basis of this study comprised of 140 
cases of   
CT/USG guided core needle biopsy lesions of the lung  from the Institute  of 
pathology, Madras Medical College, Chennai .The study period is from May 
2005 to May 2007. 
 The biopsy specimens were subjected to meticulous microscopic 
examinations. The specimens were fixed in 10% neutral buffered 
formaldehyde, processed routinely and embedded in paraffin.  
 Histological Sections (5 to 6 µm)  were  routinely stained with 
Hematoxylin and Eosin stains and special stains  like PAS (periodic acid - 
Schiff) was done in selected cases. Additional  sections were cut from 
paraffin embedded  tumor tissue for immuno histochemistry.  Due to the 
cost restriction, IHC could not be done for all the cases in the present study.   
I. HEMATOXYLIN AND EOSIN 
1. Dewax Sections.  Hydrate through  graded alcohols to water. 
2. Stain in Harris hematoxylin for 5 minutes. 
3. Wash well in running tap water. 
4. Differentiate in 1% acid alcohol. 
5. Wash well in tap water until sections are again blue for 10  
             to 15 minutes. 
6. Stain in 1% eosin for 1 to 2 minutes. 
7. Wash in running tap water for 1 to 5 minutes. 
8. Dehydrate through alcohols, clear in xylol and mount is DPX. 
II. PAS TECHNIQUE  
1. Dewax sections and bring to distilled water. 
2. Treat with periodic acid for 5 minutes. 
3. Wash well with several changes of distilled water. 
4. Cover with Schiffs solution for 15 minutes. 
5. Wash in running tap water for 5 – 10 minutes. 
6. Stain nuclei with Harris hematoxylin differentiating as         
           appropriate in acid-alcohol and blueing as usual. 
7. Wash in water. 
8. Rinse in absolute alcohol. 
9. Clear in xylene and mount.  
 
Result: 
                      Glycogen of cytoplasm of tumor cells stain magenta and the 
nucleus stains blue 
                  
                            
                             IMMUNO HISTOCHEMICAL TECHNIQUE 
       This test was done for selected cases like poorly differentiated 
carcinoma, small cell carcinoma and adenocarcinoma which had no 
histological features in light microscopy. 
 The test was based on Avidin biotin complex (ABC) technique (Heat 
mediated antigen retrieval) 
STAINING PROTOCOL 
REAGENTS 
1. 2% Hydrogen peroxide solution 
  H2o2    -  2 ml 
  Methanol  - 70 ml 
  Tris buffer  - 30 ml 
2. Antigen Retrieval Solution 
 A. Citrate Buffer (stock) 
  Citric acid   -  5.25 gm 
  Distilled Water - 500 ml 
B. Sodium Citrate (stock) 
Sodium Citrate - 7.35 gm 
Distilled water - 500 ml 
Citrate buffer working solution 
  A Solution  - 9 ml 
  B Solution  - 41 ml 
  made upto 500 ml at PH - 6.0 
v 
3. TRIS Buffer 
Tris     - 3.025 gm 
Sodium Chloride  - 40 gm 
Ammonium Choloride - 22 ml 
Made upto 5 litres at PH of 7.6. 
4. Primary Mouse antibody against inhibin  
5. Secondary biotinylated  antibody to mouse immuno globulin6.
 Substrate to the enzyme 
7. Chromogen Diamino benzidine (DAB) 
8. Harris Hematoxylin Counterstain 
9. DPX mountant 
10. Grades of alcohol and xylene  
STAINING PRINCIPLE  
 In the Peroxidase anti-peroxidase (PAP) method, the PAP reagent 
consists of antibody against horse radish peroxidase and horse radish 
peroxidase antigen in the form of stable immune complexes.  This is linked 
to the primary antibody against the antigen to be demonstrated (cytokeratin 
or synaptophysin in this case)                                       through a secondary 
antibody.  This secondary antibody is specific to the antigenic determinant 
present on the primary antibody.  The presence is visualized by a substrate 
to the peroxidase linked to a chromogen  
STEPS OF THE PROCEDURE 
1. This technique is done on formalin fixed and paraffin embedded 
sections.  Four micron sections to be taken on salanized slides. 
2. Paraffin wax is removed from the slides mounted tissue sections by 
xylene I, xylene II, xylene III, each 5 minutes. 
3. Dewaxed sections are then rehydrated by sequentially placing in 
absolute alcohol, 90% and 70% alcohol, 3 minutes each. 
4. The slides are placed in running tap water for 10 minutes. 
5. Then slides are transferred to distilled water - 5 minutes. 
6. Endogenous peroxidase in the tissue sections is blocked using 3% 
H2O2 in methanol for 30 minutes. 
7. Slides are washed in running tap water - 15 minutes 
8. Then slides are rinsed in distilled water for 10 minutes. 
9. About 3 litre of sodium citrate buffer is brought to boil in the 
pressure cooker without sealing the lid. 
10. The slides with sections attached are placed in metal racks and 
lowered into the        boiling citrate solution. 
11. The pressure cooker is sealed and brought to full pressure.  Heat 
timing begins when full pressure is reached, wait for 3 whistles. 
12. Immediately, the cooker is placed in a sink containing cold tap water 
for 5-10 minutes, then rinsed in running tap water. 
13. Slides are placed in distilled water for 5 minutes. 
14. The slides are then washed with 3 rinses of Tris buffer solution, PH 
7.6 for 5 minutes each. 
15. The sections are covered with normal human serum for monoclonal 
(1/10) dilution, swine serum for polyclonal 1/10 dilution. 
16. The blocked serum solution is tipped off the slide and replaced with 
100-200 micro litres of primary anti body for 45 minutes.   
17. The slides are then washed with 3 changes of TBS for 5 minutes. 
18. Sections are covered with second layered antibody biotinylated 
mouse immunoglobulin 1/400 dilution for 45 minutes at room 
temperature. 
19. The slides are then washed with 3 changes of TBS, 5 minutes each. 
20. Sections are then covered with streptavidin 1/800 dilution for 4 
minutes at room temperature. 
21. The slides are then rinsed with 3 charges of Tris buffer solution, 5 
minutes each. 
22. Sections are covered with DAB solution for (Substrate Chromogen) 
10 minutes at room temperature. 
23. The slides are then rinsed with distilled water for 5 minutes, then in 
running tap water for 5 minutes. 
24. The sections are counterstained with Harris haematoxylin for 30 
seconds, then washed in running tap water. 
25. The slides are placed in Scott's solution for 3 minutes. 
26. Slides are rewashed with distilled water, the dehydrated taking 
through 90% alcohol, absolute alcohol and xylene. 
27. Slides are mounted with DPX. 
SUMMARY OF THE PROCEDURE 
Preparation Protocol : 
* Prepare wash buffer solution 
* Deparaffinise and rehydrate specimens 
* Epitope retrieval 
* Prepare substrate chromogen solution 
* Apply peroxidase blocking reagent. 
 
 
                                          DISCUSSION 
                                        This study deals with the various types of lung 
tumors diagnosed on CT/USG guided core needle biopsies obtained from 
patients in the age group of 13 to  80 years   in the period between may 2005 
to may 2007.                                       
                                                 A total of 140 cases have been studied .Of 
those 140 cases 32 cases have been reported as inadequate samples due to 
the various reasons being due to materials containing normal lung 
parenchyma, specimens too small and distorted to make a diagnosis, no 
material in the specimen and the presence of necrotic , inflammatory and 
fibrotic material.(Figs 32,33,34). 
 
 
Of the remaining 108 cases 62 cases were diagnosed as squamous cell 
carcinoma(57%),30 cases  diagnosed as adenocarcinoma(28%),5  cases  
diagnosed as small cell carcinomas(4%),3 cases diagnosed as  
undifferentiated carcinomas ,2 cases diagnosed as  mucoepidermoid 
carcinoma,1 case each of an  adenoid cystic carcinoma,  inflammatory 
myofibroblastic tumor,  bronchioalveolar carcinoma and carcinoid was 
diagnosed. 
 
    Regarding the sex incidence, out of 108 cases 88 cases were  
males(81%),and 20 cases  were females(19%).Of 62 cases diagnosed as 
squamous cell carcinomas, 60 cases  were  males (96.8%) and 2 cases  were  
females(3.2%) with male female ratio of 4.4:1.Of 30 cases of 
adenocarcinomas, 17  cases were  males(56.6%)  and 13 cases were 
females(44.4%) with male female ratio of  1.3:1. All the 5  cases diagnosed 
as small cell carcinomas were  males.1  case of  adenoid cystic carcinoma 
reported  was a  male  whereas  out of  2 cases  of mucoepidermoid 
carcinoma reported,1 case each of a male and a female was found.  1 case of 
bronchioalveolar carcinoma reported was a female. The single case of 
inflammatory myofibroblastic tumor was a female patient. 
 
 
 
HISTOMORPHOLOGY OF LUNG TUMORS ON CT/USG GUIDED 
BIOPSIES 
SQUAMOUS CELL CARCINOMA 62 
ADENOCARCINOMA 30 
SMALL CELL CARCINOMA 5 
UNDIFFERENTIATED CARCINOMA 3 
MUCOEPIDERMOID CARCINOMA 2 
ADENOSQUAMOUS CARCINOMA 2 
ADENOIDCYSTIC CARCINOMA 1 
CARCINOID 1 
BRONCHIOALVEOLAR CARCINOMA 1 
INFLAMMATORYMYOFIBROBLASTIC TUMOR 1 
TOTAL 108 
 
 
 
 
         Regarding the site of  prevalence of tumors  out of 108 cases 73 cases 
were seen  in the right side of the lung(67.5%) and 35 cases  in the left  side 
of the lung(32.5%).The lobar distribution was as follows:35 cases  in the 
right upper lobe(32.4%),16 cases  in the right middle lobe( 15.5% ), 22 
cases  in the right lower lobe(19.8%),19 cases  in the left upper 
lobe(17.5%),4 cases  in the lingual(3.7%) and 12 cases  in the left lower 
lobe(11.1%). 
SITE OF PREVALANCE OF LOBES 
 Upper Middle Lower TOTAL 
Rt.lung 35 16 22 73 
Lt. lung 19 4 12 35 
 
 
 
The age groups are divided into 4 groups and the 108 neoplastic lesions 
were analyzed with respect to each decade 
                                                 GROUP A:                                <30yrs 
                                                 GROUP B:                             30-49yrs 
                                                 GROUP C:                              50-69yrs 
                                                 GROUP D:                                 >70yrs                                                
GROUP A (<30 years):   
                       In this age group,1 case has been reported(n=1).The case was  
a  male  patient  aged 13 years  and the histopathological diagnosis turned  
out to be adenocarcinoma..According to Yutaka Mizushima et al, most 
number of cases occurs in females with a percentage of 62% and 
adenocarcinoma constitutes the predominant histological type. . 
    GROUPB (30-49 years): 
                       In this age group of 30 to 49 years,out of  108 cases ,29 cases 
had been reported(n=29).Total no of   males were 19 (n=29)  constituting 
65% and the female cases were 10(35%).Squamous cell carcinoma 
constituted 15 cases (52 %), adenocarcinoma constituted  9 cases (31%)  
and one case each of mucoepidermoid carcinoma, undifferentiated 
carcinoma, adenosquamous carcinoma, bronchioalveolar carcinoma and 
inflammatory myofibroblastic tumor  was reported(3.4%).According to  
Yutaka Mizushima, most of the cases occurred in males with a percentage 
of 61% and the predominant histological type is adenocarcinoma.. 
GROUPC (50-69 years): 
                              This age group constituted the predominant group where  
out of 108 cases, 68  cases were seen (63%).Out of 68 cases ,58 cases were 
males(81.7%) and females  numbered 10(19.3%) with male female ratio of  
5.8:1.Out of 68 cases ,43 cases were squamous cell carcinoma(63%), 
adenocarcinoma numbered 17 cases (25%),3 cases of small cell 
carcinoma(4.4%),2 cases of undifferentiated carcinoma (2.8%) and 1 case 
each of  adenosquamous carcinoma, mucoepidermoid carcinoma ,adenoid 
cystic carcinoma (1.6%)   
              According to Mizushima et al, 81 % percentage of cases occurred 
in males and the predominant histological entity was adenocarcinoma(37%) 
. 
GROUP D (>70 years): 
                     In this age group, 10 cases have been reported. Squamous cell 
carcinoma constituted 4 cases (40%), adenocarcinoma constituted 3 cases 
(30%) , 2 cases of small cell carcinomas(20%) and 1 case of carcinoid  was 
reported. 
 
 
 
AGE DISTRIBUTION OF LUNG CARCINOMAS 
 <30 yrs 30-49yrs 50-69yrs >-70yrs 
SQUAMOUS CELL 
CARCINOMA 0 15 43 4
ADENOCARCINOMA 1 9 17 3
SMALL CELL 
CARCINOMA 0 0 3 2
UNDIFFERENTIATED 
CARCINOMA 0 1 2 0
MUCOEPIDERMOID 
CARCINOMA 0 1 1 0
ADENOSQUAMOUS 
CARCINOMA 0 1 1 0
ADENOIDCYSTIC 
CARCINOMA 0 0 1 0
BRONCHIOALVEOLAR 
CARCINOMA 0 1 0 0
CARCINOID 0 0 0 1
INFL MYO 
FIBROBLASTIC TUMOR 0 1 0 0
TOTAL 1 29 68 10
 
 
  
 
 
 
RELATIVE PERCENTAGE OF LUNG TUMORS ACCORDING TO 
AGE GROUP 
 
  <30 YRS 30-49 YRS 50-69 YRS >70 YRS 
SQUAMOUS CELL 
CARCINOMA 0% 52% 63.20% 40%
ADENOCARCINOMA 100% 31% 25% 30%
SMALL CELL CARCINOMA 0% 0% 4.40% 20%
UNDIFFERENTIATED 
CARCINOMA 0% 3.40% 2.90% 0%
MUCOEPIDERMOID 
CARCINOMA 0% 3.40% 1.50% 0%
ADENOSQUAMOUS 
CARCINOMA 0% 3.40% 1.50% 0%
ADENOIDCYSTIC 
CARCINOMA 0% 0% 1.50% 0%
BRONCHIOALVEOLAR 
CARCINOMA 0% 3.40% 0% 0%
CARCINOID 0% 0% 0% 10%
INFLAMMATORY 
MYOFIBROBLASTIC 
TUMOR 0% 3.40% 0% 0%
MALE:FEMALE 1:00 19:10 58:10:00 10:00
     
 
 
  
 
SQUAMOUS CELL CARCINOMA: 
                                                          This particular pathological entity 
constituted the predominant neoplasm in our study .Out of 108 cases 62 
cases  belonged to this category(57%)showing a male predominance with 60 
cases (97.1%).The predominant  age group of involvement was 50-69 years 
(n=68) where 43 cases have been reported constituting  63%..No case was 
recorded under the age of 30 years. 4 cases were seen above 70 years. 
                                Majority of squamous cell carcinomas were found in the 
right upper lobe constituting 39%(n=24) followed by 7 cases in the right 
middle lobe, 8 cases in the right lower lobe, 14 cases in the left upper lobe, 1 
case in the lingual and 8 cases in the left lower lobe .This shows the 
prevalence of squamous cell carcinoma in the upper lobes thus correlating 
with the literature3 
                                                Squamous cell carcinoma was diagnosed based on 
certain features like intercellular bridges and keratin formation. (Figs 1, 2, 3) 
In the absence of the above features, squamous cell carcinoma can be 
diagnosed on small biopsies based on the intraepithelial insitu like extension 
along the bronchus which is not seen in adeno or small cell carcinoma31. 
 
 
 
 
SITE OF PREVALANCE OF SQUAMOUS CELL CARCINOMA 
  Upper LOBE MiddleLOBE/LINGULA Lower LOBE 
R LUNG 24 7 8 
LLUNG 14 1 8 
 
 
 
                   Though all our cases demonstrated keratinisation and 
intercellular bridges, intraepithelial insitu like extension could not be seen in 
any of the cases. , 
SQUAMOUS CELL CARCINOMA –AGE AND SEX DISTRIBUTION 
      Male Female PERCENT 
<30 YRS 0 0 0 
30-49YRS 13 2 24.1 
50-69YRS 43 0 69.6 
>-70 YRS 4 0 6.3 
TOTAL 60 2 100 
 
 
 
ADENOCARCINOMA: 
                                        This pathological entity constituted the 
predominant neoplasm next to squamous cell carcinoma. Out of the total 
108 cases, 30 cases belonged  to this category.(28%).The predominant age 
group was 50-69 years where 17 cases were noted(56.6%).In the age group 
of 30-49 years , 9 cases were noted. One case was seen under the age of 30 
years and 3 cases above 70 years .In our study one case of adenocarcinoma 
was reported under the age group of 30 years .Out of 30 cases, 17 cases 
were males (56.6%) and females constituted 13 cases (44.4%). 
                        Majority of adenocarcinomas were found  in the right lower 
lobe(33.3%) followed by 5 cases each in the right middle and lower lobes,1 
case in the lingula,and 4 cases each in the left upper and lower lobes. 
SITE OF PREVALANCE OF ADENOCARCINOMA 
 
  ULOBE MLOBE/LINGULA LLOBE 
R LUNG 5 5 11 
LLUNG 4 1 4 
 
 
 
  
Adenocarcinoma was diagnosed base on the gland formation and mucin 
production. (Figs 4, 5, 6). The special stain PAS was employed for 
confirmation of the diagnosis in 18 cases and all of them turned out to be 
PAS positive.( Figs 7, 8 ) Cytokeratin7 immunohistochemical stain was 
positive in a case which did not have mucin formation and glandular 
differentiation in H and E sections.(Figs 9,10 ). 
 
 
 
 
ADENOCARCINOMA AGE AND SEX INCIDENCE 
  M F PERCENT 
<30 YRS 1 0 3.3 
30-49 YRS 4 5 30 
50-69 YRS 9 8 55.6 
>- 70 YRS 3 0 11.1 
TOTAL 17 13 100 
 
 
 
SMALL CELL CARCINOMA: 
                                              5 cases of small cell carcinoma were reported 
constituting 4% of the total cases.All the cases were males. The 
predominant age group was 50-69 years where 3cases (60%) were seen and 
the remaining two cases were found in the age group of >70 years cases. All 
cases demonstrated histo pathological features like hyper chromatic nucleus, 
inconspicuous nucleoli and fine stippled chromatin which are the essential 
diagnostic features of this tumor1  (Figs 11,12,) and confirmed by 
application of NSE to a single case.(Figs 13 ). 
 
SMALL CELL CARCINOMA- AGE AND SEX DISTRIBUTION 
 
  M F PERCENT 
<30 YRS 0 0 0
30-49YRS 0 0 0
50-69YRS 3 0 60
>-70YRS 2 0 40
TOTAL 5 0 100
 
 
 UNDIFFERENTIATED CARCINOMA: 
                                      Undifferentiated carcinoma constituted 3 cases (3%) 
of the total number of cases.2 cases were males and the other was a female.2 
cases were found in the age group of 50-69 years and the other case was 
found in the age group of 30-49 years. Microscopically the cells composed 
of sheets of undifferentiated cells exhibiting cytological atypia. (Figs 14,15) 
. Immuno histochemistry of this tumor with a panel of cytokeratins and NSE 
was done and was found to be negative. 
 
 
 
 
UNDIFFERENTIATED CARCINOMA-AGE AND SEX DISTRIBUTION 
  M F PERCENT 
<30 YRS 0 0 0 
30-49 YRS 0 1 33.40% 
50-69 YRS 2 0 66.60% 
>-70 YRS 0 0 0 
TOTAL 2 1 100% 
    
    
    
 
 
 
CARCINOID:  
                          One case of carcinoid was reported in a 70 year old male 
patient. It was found in the right middle lobe. Microscopically the tumor 
cells are polygonal with uniform round nucleus with fine chromatin and 
moderate amount of eosinophilic cytoplasm. (Figs 28, 
29).Immunohistochemistry could not be done to this case due to the 
inadequacy of the material. 
ADENOID CYSTIC CARCINOMA: 
                                                           In our study one case of this entity had 
been reported .He was a 55 year old male patient and it is located in the 
right lower lobe. According to Hilal Alunoz et al, about 85% of cases 
occurred in the trachea with only 10 to 15%cases occurred in the periphery 
and the most common histological pattern is cribriform pattern. In our study, 
the pattern is cribriform pattern (Figs 23, 24) and confirmed by PAS stain. 
(Fig 25) 
MUCOEPIDERMOID CARCINOMA: 
                                                              In our study one case of this 
particular entity has been reported. She is a 47 year old female patient and 
the lesion is found in the right upper lobe. Microscopically the tumor 
demonstrated squamoid cells, mucinous cells, intermediate cells and clear 
cells and confirmed by PAS (Figs 16, 17, 18, 19).  According to Xiuli Liu et 
al, these tumors predominantly occur in children and present with intra 
luminal bronchial mass with equal sex incidence. 
 
MUCOEPIDERMOID CARCINOMA-AGE AND SEX 
DISTRIBUTION 
 M F PERCENT 
<30 YRS 0 0 0 
30-49 YRS 1 0 50 
50-69 YRS 0 1 50 
>-70 YRS 0 0 0 
TOTAL 1 1 100% 
 
 
 
 
 
INFLAMMATORY MYOFIBROBLASTIC TUMOR: 
                                                                                    In our study, one case 
of this particular entity had been reported. She was a female patient aged 39 
years, presented with a solitary mass in the right middle lobe correlating 
with Mahale.A et al which stated that this particular tumor occurs more 
common in young females occurring predominantly as a solitary pulmonary 
lesion. Microscopically the tumor composed of spindle shaped cells, 
lymphocytes and plasma cells. (Figs 30,31). 
ADENOSQUAMOUS CARCINOMA: 
                                                               In our study,2 cases of 
adenosquamous carcinoma had been reported, one being a 49 year old male 
and the other  being a 58 year old lady. Both those cases were found in the 
right lower lobe .The adenocarcinomatous component composes 20% of the 
tumor confirmed with PAS stain. (Figs 20,21,22). These features correlated 
with Shin o Takamari et al who stated that for confirmation of 
adenosquamous carcinoma required either components accounting more 
than 10%. 
 
 
 
ADENOSQUAMOUS CARCINOMA-AGE AND SEX 
DISTRIBUTION 
 
  M F PERCENT 
<30 YRS 0 0 0 
30-49 YRS 1 0 50 
50-69 YRS 0 1 50 
>-70 YRS 0 0 0 
TOTAL 1 1 100 
 
 
 
 
 
BRONCHIOALVEOLAR CARCINOMA: 
                                                       In our study, one case of bronchioalveolar 
carcinoma was reported in a 39 year old lady who presented with a solitary 
mass in the lingual. Microscopically it was composed of columnar to 
cuboidal cells with mild nuclear atypia with no invasion of the surrounding 
stroma (Figs 26, 27) thus correlating with the literature.13 
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                                       SUMMARY AND CONCLUSION 
                                                This study takes into account, the 
available      data ie,age, sex, site of involvement, 
histomorphological features, special stains and  immunochemical 
methods in arriving at the following observations. 
1) Out of 140 cases, 77% of cases were adequate biopsies and 
23% were inadequate as far as diagnosis was concerned. 
2) Regarding the age group, predominant number of cases was 
found in 50-69 years with the frequency of 63%. 
3) Males were the predominant sex involved with the male 
female ratio of 4.4:1. 
4) Regarding the histopathological type, squamous cell 
carcinoma was the most common over other types with 57%. 
5) The site of prevalence of the tumors was found in the right 
upper lobe in 32.4% of cases. Squamous cell carcinoma 
showed a predilection for involving the upper lobes and 
adenocarcinoma involved the lower lobes. 
6) The youngest age of involvement was 13 years and the oldest 
age was 80 years with the mean of 46.5 years. 
7)  Rare cases of inflammatory myofibroblastic tumor, 
adenoidcystic carcinoma and mucoepidermoid carcinoma 
were documented in our study. 
8) Immunohistochemistry is useful in selected cases in arriving at 
the diagnosis. 
                  To conclude, CT/USG guided core needle biopsy 
specimens are extremely valuable in the preoperative 
diagnosis of various histopathological entities especially in 
differentiating small cell carcinoma (SCLC) from non small 
cell carcinomas (NSCLCS) as treatment protocol varies 
between these entities, by strictly adhering to the already 
proposed histomorphological criteria . 
                     The procedure been properly done and adequate 
material been obtained, this core needle biopsy sample will be 
extremely useful in a confident diagnosis thus obviating the 
need for thoracotomy in most cases. 
                   
 
 
 
 
 
 
 
 
 
 
 
 
 
              
 
Fig 1  Squamous cell carcinoma –H&E (40 X) 
              
 
Fig 2 Squamous cell carcinoma-H&E (100X) 
                     
 
Fig 3 Squamous cell carcinoma –H & E (400 X) 
 
 
Fig 4 Adenocarcinoma-H&E (40X) 
 
 
 
Fig 5:Adenocarcinoma –H&E(100X) 
 
 
 
 
Fig 6:Adenocarcinoma-H&E(400X) 
 
Fig 7 Adenocarcinoma –PAS (100X) 
 
 
Fig 8 Adenocarcinoma –PAS (400X) 
 
 
Fig 9:Adenocarcinoma positive for cytokeratin  7(100X) 
 
 
 
 
Fig 10:Adenocarcinoma positive for cytokeratin  7(400X) 
 
                                
Fig 11-Small cell carcinoma H&E (100X) 
 
 
 
 
 
Fig 12-Small cell carcinoma H&E (400X) 
 
Fig 13: Small cell carcinoma positive for Neuron specific enolase (100x) 
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Fig 14: Undifferentiated carcinomaH &E(40X) 
 
                             
 
Fig 15: Undifferentiated carcinoma-H&E (400X) 
 
 
 
Fig 16:Mucoepidermoid carcinoma-H&E(40X) 
 
 
Fig 17:Mucoepidermoid carcinoma –H&E(100X) 
 
 
 
Fig 18:Mucoepidermoid carcinoma-H&E(400X) 
 
 
 
 
 
 
Fig 19:Mucoepidermoid carcinoma-Positive for PAS(400X) 
 
 
 
 
 
 
 
Fig 20:Adenosquamous carcinoma-H&E(100X) 
 
 
 
Fig 21:Adenosquamous carcinoma-H&E(400X) 
 
 
Fig 22:Adenosquamous carcinoma-H&E(400X) 
 
Fig 23:Adenoidcystic carcinoma-H&E(100X) 
 
 
 
Fig 24:Adenoidcystic carcinoma-H&E(400X) 
 
 
 
 
Fig 25:Adenoidcystic carcinoma-Positive for PAS(400X) 
 
 
 
 
 
Fig 26:Bronchioalveolar carcinoma-H&E(100X) 
 
    
Fig 27: Bronchioalveolar carcinoma-H&E (400X) 
 
 
 
 
 
Fig 28: carcinoid –H&E (40X) 
 
 
Fig 29: Carcinoid-H&E(100X) 
 
 
 
 
 
 
 
Fig 30: Inflammatory myofibroblastic tumor-H&E(100X) 
 
 
 
Fig 31: Inflammatory myofibroblastic tumor-H&E(400X) 
 
NONDIAGNOSTIC BIOPSIES 
 
 
 
 
 
 
 
Fig 32 : Inflammation and  fibrosis-H&E(100X)                         Fig 33 : Necrosis 
and hemorrhage-H&E(100X) 
 
 
Fig 34 : Normal lung parenchyma-H&E 
(100X)  
 
 
 
 
 
 
 
 
 
 
 
 
 
                
                                  
                                                                                                          
                           
 S.NO 
BIOP 
NO 
AG
E SEX SIDE LOBE 
HISTOPATHOLOGICAL 
DIAGNOSIS 
 1 27/05 67 M L UL NONDIAGNOSTIC 
 2 45/05 60 M R UL SMALL CELL CARCINOMA 
 3 57/05 62 M L LL SQUAMOUS CELL CARCINOMA 
 4 144/05 65 M L LIN NONDIAGNOSTIC 
 5 147/05 53 M L UL SQUAMOUS CELL CARCINOMA 
 6 157/05 62 M R ML SQUAMOUS CELL CARCINOMA 
 7 177/05 35 M L UL SQUAMOUS CELL CARCINOMA 
 8 434/05 39 F R ML 
INFLAMMATORY 
MYOFIBROBLASTTUMOR  
 9 550/05 72 M R ML SMALL CELL CARCINOMA 
 10 658/05 42 M R UL SQUAMOUS CELL CARCINOMA 
 11 1059/05 69 M R UL SQUAMOUS CELL CARCINOMA 
 12 1114/05 60 M R UL SQUAMOUS CELL CARCINOMA 
 13 1162/05 56 M L UL ADENOCARCINOMA 
 14 1174/05 64 M L UL ADENOCARCINOMA 
 15 1189/05 41 M L UL SQUAMOUS CELL CARCINOMA 
 16 1218/05 53 M L UL SQUAMOUS CELL CARCINOMA 
 17 1306/05 56 M L LL SQUAMOUS CELL CARCINOMA 
 18 1416/05 55 M R UL NONDIAGNOSTIC 
 19 1442/05 60 F R UL ADENOCARCINOMA 
 20 1460/05 53 M L UL NONDIAGNOSTIC 
 21 1520/05 55 M L LL SQUAMOUS CELL CARCINOMA 
 22 1549/05 65 M L UL SQUAMOUS CELL CARCINOMA 
 23 1757/05 60 M L UL SQUAMOUS CELL CARCINOMA 
 24 1771/05 56 M R LL SQUAMOUS CELL CARCINOMA 
 25 1779/05 58 M R UL SQUAMOUS CELL CARCINOMA 
 26 1816/05 50 F R ML MUCOEPIDERMOID CARCINOMA 
 27 2009/05 40 F R ML ADENOCARCINOMA 
 28 2035/05 30 F R UL NONDIAGNOSTIC 
 29 2065/05 47 M L UL NONDIAGNOSTIC 
 30 2187/05 64 M L UL SQUAMOUS CELL CARCINOMA 
 31 2339/05 70 M R ML SQUAMOUS CELL CARCINOMA 
 32 2432/05 59 M L UL NONDIAGNOSTIC 
 33 2507/05 52 M L LIN NONDIAGNOSTIC 
 34 2546/05 66 F L LL NONDIAGNOSTIC 
 35 2617/05 35 M L UL NONDIAGNOSTIC 
 36 2628/05 44 M R ML SQUAMOUS CELL CARCINOMA 
 37 4864/05 63 M R UL SQUAMOUS CELL CARCINOMA 
 38 4872/05 73 M L UL ADENOCARCINOMA 
 39 4901/05 32 M R ML ADENOCARCINOMA 
 40 4994/05 70 M L UL SQUAMOUS CELL CARCINOMA 
 41 5058/05 51 M L UL SQUAMOUS CELL CARCINOMA 
 42 5261/05 62 M R UL SMALL CELL CARCINOMA 
 43 5345/05 70 M R ML  CARCINOID 
 44 5747/05 46 F L UL SQUAMOUS CELL CARCINOMA 
 45 5748/05 51 M R UL NONDIAGNOSTIC 
 46 5789/05 67 M R UL ADENOCARCINOMA 
 47 5807/05 60 M L LL SQUAMOUS CELL CARCINOMA 
 48 5986/05 45 M R UL SQUAMOUS CELL CARCINOMA 
 49 6295/05 55 M R ML SQUAMOUS CELL CARCINOMA 
 50 6334/05 56 M R UL NONDIAGNOSTIC 
 51 6463/05 62 M R ML NONDIAGNOSTIC 
 52 6472/05 57 M R UL SQUAMOUS CELL CARCINOMA 
 53 6497/05 65 M R UL SQUAMOUS CELL CARCINOMA 
 54 6518/05 65 M R UL SQUAMOUS CELL CARCINOMA 
 55 6622/05 60 F L UL NONDIAGNOSTIC 
 56 6790/05 65 F L LL ADENOCARCINOMA 
 57 6851/05 54 M R UL SMALL CELL CARCINOMA 
 58 6911/05 13 M R LL ADENOCARCINOMA 
 59 6950/05 45 F R LL ADENOCARCINOMA 
 60 6994/05 66 M R LL NONDIAGNOSTIC 
 61 64/06 45 M R LL ADENOCARCINOMA 
 62 218/06 50 M R LL  SQUAMOUS CELL CARCINOMA 
 63 238/06 45 M L LL NONDIAGNOSTIC 
 64 252/06 53 M R LL SQUAMOUS CELL CARCINOMA 
 65 254/06 72 M R LL SQUAMOUS CELL CARCINOMA 
 66 270/06 60 M R UL SQUAMOUS CELL CARCINOMA 
 67 273/06 57 M R UL NONDIAGNOSTIC 
 68 301/06 43 M R LL SQUAMOUS CELL CARCINOMA 
 69 309/06 48 M R LL NONDIAGNOSTIC 
 70 322/06 65 M L LL NONDIAGNOSTIC 
 71 339/06 60 M R UL NONDIAGNOSTIC 
 72 348/06 58 M L LL NONDIAGNOSTIC 
 73 383/06 59 M L UL SQUAMOUS CELL CARCINOMA 
 74 392/06 67 M R UL SQUAMOUS CELL CARCINOMA 
 75 398/06 38 M L UL SQUAMOUS CELL CARCINOMA 
 76 421/06 67 M R LL SQUAMOUS CELL CARCINOMA 
 77 434/06 55 M R LL ADENOIDCYSTIC CARCINOMA 
 78 477/06 45 M L LL SQUAMOUS CELL CARCINOMA 
 79 499/06 58 F R UL NONDIAGNOSTIC 
 80 542/06 48 F R LL ADENOCARCINOMA 
 81 55O/06 60 M R LL NONDIAGNOSTIC 
 82 558/06 60 M R LL NONDIAGNOSTIC 
 83 592/06 52 M R LL 
 UNDIFFERENTIATED 
CARCINOMA 
 84 661/06 69 M R LL NONDIAGNOSTIC 
 85 689/06 49 M R LL  ADENOSQUAMOUS CARCINOMA 
 86 731/06 60 M L LL ADENOCARCINOMA 
 87 744/06 53 M R UL NONDIAGNOSTIC 
 88 819/06 58 F R LL  ADENOSQUAMOUS CARCINOMA 
 89 876/06 60 M R LL SQUAMOUS CELL CARCINOMA 
 90 879/06 54 M R LL ADENOCARCINOMA 
 91 1080/06 40 M L UL SQUAMOUS CELL CARCINOMA 
 92 1086/06 56 M R UL SQUAMOUS CELL CARCINOMA 
 93 1138/06 67 M R LL ADENOCARCINOMA 
 94 1190/06 35 F R LL ADENOCARCINOMA 
 95 1238/06 59 M R UL SQUAMOUS CELL CARCINOMA 
 96 1239/06 65 M R LL ADENOCARCINOMA 
 97 1291/06 44 M R UL ADENOCARCINOMA 
 98 1562/06 65 M R ML SQUAMOUS CELL CARCINOMA 
 99 1716/06 64 M R LL 
 UNDIFFERENTIATED 
CARCINOMA 
 100 1808/06 67 M R UL SQUAMOUS CELL CARCINOMA 
 101 1875/06 70 M R LL SQUAMOUS CELL CARCINOMA 
 102 2111/06 60 M R LL SQUAMOUS CELL CARCINOMA 
 103 2803/06 57 M R LL ADENOCARCINOMA 
 104 2817/06 60 M R UL SQUAMOUS CELL CARCINOMA 
 105 2938/06 60 M R LL SQUAMOUS CELL CARCINOMA 
 106 3062/06 48 M R&L ALL NONDIAGNOSTIC 
 107 3509/06 45 F L 
LINGU
LA 
BRONCHOALVEOLAR 
CARCINOMA 
 108 3514/06 40 M R LL ADENOCARCINOMA 
 109 3560/06 19 M R LL NONDIAGNOSTIC 
 110 3631/06 20 M R LL NONDIAGNOSTIC 
 111 3660/06 46 F R UL ADENOCARCINOMA 
 112 3707/06 56 M L UL SQUAMOUS CELL CARCINOMA 
 113 3715/06 68 M L 
LINGU
LA ADENOCARCINOMA 
 114 3734/06 51 F L LL NONDIAGNOSTIC 
 115 3805/06 58 M R ML NONDIAGNOSTIC 
 116 3834/06 56 F L LL ADENOCARCINOMA 
 117 3848/06 40 M L 
LINGU
LA SQUAMOUS CELL CARCINOMA 
 
 
 
 
 
 
 
 
 118 3892/06 49 M L UL SQUAMOUS CELL CARCINOMA 
 119 3972/06 58 M L LL SQUAMOUS CELL CARCINOMA 
 120 3997/06 52 M L LL ADENOCARCINOMA 
 121 4025/06 61 M R LL SQUAMOUS CELL CARCINOMA 
122 4074/06 30 F R LL 
UNDIFFERENTIATED 
CARCINOMA 
123 4104/06 60 M R ML ADENOCARCINOMA 
124 4122/06 56 F R ML ADENOCARCINOMA 
125 4187/06 55 M R ML SQUAMOUS CELL CARCINOMA 
126 4632/06 42 M L LL SQUAMOUS CELL CARCINOMA 
127 5026/06 42 M R UL SQUAMOUS CELL CARCINOMA 
128 5321/06 70 M R LL ADENOCARCINOMA 
129 6084/06 50 F R UL ADENOCARCINOMA 
130 6351/06 58 M R ML SQUAMOUS CELL CARCINOMA 
131 6364/06 50 F R LL NONDIAGNOSTIC 
132 8162/06 47 F R UL SQUAMOUS CELL CARCINOMA 
133 8213/06 80 M R LL SMALL CELL CARCINOMA 
134 268/07 55 M R UL SQUAMOUS CELL CARCINOMA 
135 351/07 53 M L LL SQUAMOUS CELL CARCINOMA 
136 384/07 50 F L LL ADENOCARCINOMA 
137 2476/07 72 M R UL ADENOCARCINOMA 
138 4849/07 71 M R UL MUCOEPIDERMOID CARCINOMA 
139 5052/07 
          
57 M R UL SQUAMOUS CELL CARCINOMA 
               
140 
5121/07           
65 
M R UL SQUAMOUS CELL CARCINOMA 
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